MONTREAL, CANADA--(Marketwire - September 09, 2008) - ART Advanced
Research Technologies Inc. ("ART") (TSX: ARA), a Canadian medical
device company and a leader in optical molecular imaging products for
the healthcare and pharmaceutical industries, announced today that
current research relating to its molecular imaging products will be
presented at the World Molecular Imaging Congress (WMIC), being held
at the Nice Acropolis Convention Centre in Nice, France, from
September 10 to 13, 2008. ART is also featuring the Optix® and
Fenestra® preclinical product offering as an exhibitor at the event
(booth #211), in the Exhibit Hall of the Nice Acropolis Convention
Center.

Prior to the start of the meeting - on Wednesday, September 10 - ART
will hold a ART User Forum, where Optix users and research scientists
will present their work, and provide an opportunity for potential
clients to learn about new developments and applications available
for the Optix system, as well as the capability for translational
research using the SoftScan® breast imaging device. Both products are
based on the proprietary time domain technology developed by ART.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix® optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan® optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. Finally, the Fenestra® line
of molecular imaging contrast products provides image enhancement for
a wide range of preclinical Micro CT applications allowing scientists
to see greater detail in their imaging studies, with potential
extension into other major imaging modalities. ART is commercializing
some of these products in a global strategic alliance with GE
Healthcare, a world leader in mammography and imaging. ART's shares
are listed on the TSX under the ticker symbol ARA. For more
information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to
risks and uncertainties that would cause actual events to differ
materially from expectations. These risks and uncertainties are
described in ART's most recent Annual Information Form and the
financial statements for the year ended December 31, 2007, available
on SEDAR (www.sedar.com).
Contacts:
ART Advanced Research Technologies Inc.
Jacques Bedard
Chief Financial Officer
514-832-0777
jbedard@art.ca

ART Advanced Research Technologies Inc.
Dino DiCamillo, Vice President, Global Sales and
Marketing, Preclinical Research
514-832-0777
ddicamil@art.ca
www.art.ca





Copyright © Hugin AS 2008. All rights reserved.